10-K: HST Global Inc. Files 2023 Annual Report, Continues Search for Revenue Streams Amidst Ongoing Losses

HST Global Inc.'s 2023 annual report reveals the company remains in the start-up phase with no revenue, ongoing losses, and a continued search for viable business opportunities.

Summary

• HST Global Inc. has filed its annual report for the fiscal year ending December 31, 2023.
• The company is still in the start-up phase and has not commenced operations.
• HST Global reported no revenue for both 2023 and 2022.
• Operating expenses were $146,210 in 2023, slightly up from $145,074 in 2022, primarily due to increased accounting expenses.
• The company's net loss was $146,210 for 2023, compared to a net loss of $145,074 in 2022.
• As of December 31, 2023, the company had a cash balance of $1,526.
• The company has 5,248,582 shares of common stock issued and outstanding, held by approximately 602 shareholders.
• HST Global is seeking opportunities to integrate assets, rights, or other potential revenue streams, as its original business plan has not been initiated.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern due to the lack of revenue and ongoing operating costs.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the lack of revenue, ongoing losses, and the auditor's going concern opinion. The company's future is highly uncertain, and the risk of failure is significant.

Positives

• The company is actively seeking new opportunities to generate revenue and integrate assets.
• HST Global has maintained a consistent level of operating expenses year over year.
• The company has a small cash balance of $1,526.

Negatives

• HST Global has not generated any revenue in the past two years.
• The company has incurred significant net losses of $146,210 in 2023 and $145,074 in 2022.
• The company's auditor has raised concerns about its ability to continue as a going concern.
• The company has not been able to initiate its original business plan.
• The company has material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to its lack of revenue and ongoing operating costs.
• HST Global needs to raise additional capital to fund its operations and implement its business plan.
• There is no assurance that the company will be able to achieve profitability or obtain the required funding.
• The company's stock is considered a penny stock, which subjects it to additional sales practice requirements.
• The company has material weaknesses in its internal control over financial reporting.

Future Outlook

The company intends to continue seeking opportunities to integrate assets, rights, or other potential revenue streams, and will need to raise additional funds or pursue strategic transactions to achieve profitability.

Management Comments

• Management acknowledges the company has not yet established an ongoing source of revenues sufficient to cover its operating costs.
• Management plans to raise funds through public offerings and rely on officers and directors to perform essential functions with minimal compensation.
• Management has concluded that the company's disclosure controls and procedures were not effective as of December 31, 2023.

Industry Context

The company's focus on homeopathic and alternative cancer treatments places it within the niche biotechnology sector, which is characterized by high risk and high potential reward. The company's inability to generate revenue and its going concern issues are not uncommon for early-stage biotech companies.

Comparison to Industry Standards

• Many early-stage biotech companies face similar challenges in generating revenue and securing funding.
• Companies like Novavax and Sorrento Therapeutics have experienced significant volatility and financial challenges during their development phases.
• HST Global's lack of revenue and reliance on related party transactions is not uncommon for companies in the early stages of development.
• The company's cash balance of $1,526 is significantly lower than many comparable companies, indicating a higher risk of financial distress.

Corporate Governance

Related Party Transactions

• The company's executive offices are located at 150 Research Dr., Hampton VA, and are leased by The Health Network, Inc., of which Ron Howell is President.
• The company uses the office space without a formal sublease or rental agreement.
• The company has a consulting agreement with Mr. Howell, President of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month.
• Total related party notes payable as of December 31, 2023 and 2022 were $98,319 and $76,077 respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and lack of revenue.
• Employees are at risk due to the company's uncertain future and potential for ceasing operations.
• Creditors face the risk of not being repaid due to the company's financial difficulties.

Next Steps

• The company will continue to seek opportunities to integrate assets, rights, or other potential revenue streams.
• The company will need to raise additional funds to continue operations.
• The company is evaluating methods of improving its internal control over financial reporting.

Key Dates

Keywords

biotechnology, wellness centers, homeopathic treatment, cancer treatment, start-up, revenue, net loss, operating expenses, penny stock, going concern, capital raise